Bimiralisib

CAS号

1225037-39-7

分子式

C17H20F3N7O2

主要靶点

mTOR|PI3K|S6 Kinase|Others

仅限科研使用

Cat No : CM05964

Print datasheet

Synonyms

5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine|Bimiralisib|inhibit|S6Kinase|S6 Kinase|Inhibitor|Mammalian target of Rapamycin|mTOR|pS6|PQR309|PQR-309|PQR 309|pPKB|PI3Kγ|PI3Kδ|Phosphoinositide 3-kinase|PI3K|PI3Kβ|PI3K-IN-2|PI3Kα



产品信息

CAS号 1225037-39-7
分子式 C17H20F3N7O2
主要靶点 mTOR|PI3K|S6 Kinase|Others
主要通路 PI3K/Akt/mTOR 信号通路|PI3K/Akt/mTOR 信号通路|MAPK 信号通路|PI3K/Akt/mTOR 信号通路
分子量 411.38
纯度 99.88%, 此纯度可做参考,具体纯度与批次有关系,可咨询客服
储存条件 Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
别名 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine|Bimiralisib|inhibit|S6Kinase|S6 Kinase|Inhibitor|Mammalian target of Rapamycin|mTOR|pS6|PQR309|PQR-309|PQR 309|pPKB|PI3Kγ|PI3Kδ|Phosphoinositide 3-kinase|PI3K|PI3Kβ|PI3K-IN-2|PI3Kα

靶点活性

PI3Kα:1.5 nM(Kd)|PI3Kγ:25 nM(Kd)|mTOR:12 nM(Kd)|PI3Kβ:11 nM(Kd)|PI3Kδ:25 nM(Kd)

溶解度

DMSO:5 mg/mL (12.15 mM)

参考文献

1.Beaufils F, et al. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. J Med Chem. 2017 Sep 14;60(17):7524-7538.
2.Wicki A, et al. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). Eur J Cancer. 2018 Jun;96:6-16.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2